AstraZeneca Plc’s anti-platelet agent Brilinta (ticagrelor) has failed to show a significant benefit over Plavix in a Phase 3 study of patients with symptomatic peripheral artery disease (PAD) – the second trial failure this year for the drug. ---Subscribe to MedNous to access this article--- Clinical Research Company News
